This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Divieti, P. Articles by Bringhurst, F. R. Search for Related Content PubMed PubMed Citation Articles by Divieti, P. Articles by Bringhurst, F. R.

Receptors for the Carboxyl-Terminal Region of PTH(1–84) Are Highly Expressed in Osteocytic Cells¹

Endocrine Unit (P.D., K.C., R.S., H.J., F.R.B.), Massachusetts General Hospital, and Harvard Medical School, Boston Massachusetts 02114; and Chugai Pharmaceutical Company (N.I.), Ltd., Shizuoka, Japan

Address all correspondence and requests for reprints to: Paola Divieti M.D., Ph.D., Endocrine Unit, Wellman 5, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: divieti{at}helix.mgh.harvard.edu

PTH is a potent systemic regulator of cellular differentiation and function in bone. It acts upon cells of the osteoblastic lineage via the G protein-coupled type-1 PTH/PTH-related peptide receptor (PTH1R). Carboxyl fragments of intact PTH(1–84) (C-PTH fragments) are cosecreted with it by the parathyroid glands in a calcium-dependent manner and also are generated via proteolysis of the hormone in peripheral tissues. Receptors that recognize C-PTH fragments (CPTHRs) have been described previously in osteoblastic and chondrocytic cells. To directly study CPTHRs in bone cells, we isolated clonal, conditionally transformed cell lines from fetal calvarial bone of mice that are homozygous for targeted ablation of the PTH1R gene and transgenically express a temperature-sensitive mutant SV40 T antigen. Cells with the highest specific binding of the CPTHR radioligand ¹²⁵I-[Tyr³⁴]hPTH(19–84) exhibited a stellate, dendritic appearance suggestive of an osteocytic phenotype and expressed 6- to 10-fold more CPTHR sites/cell than did osteoblastic cells previously isolated from the same bones. In these osteocytic (OC) cells, expression of mRNAs for CD44, connexin 43, and osteocalcin was high, whereas that for alkaline phosphatase and cbfa-1/osf-2 was negligible. The CPTHR radioligand was displaced completely by hPTH(1–84), hPTH(19–84) and hPTH(24–84) (IC₅₀s = 20–50 nM) and by hPTH(39–84) (IC₅₀ = 500 nM) but only minimally (24%) by 10,000 nM hPTH(1–34). CPTHR binding was down-regulated dose dependently by hPTH(1–84), an effect mimicked by ionomycin and active phorbol ester. Human PTH(1–84) and hPTH(39–84) altered connexin 43 expression and increased apoptosis in OC cells. Apoptosis induced by PTH(1–84) was blocked by the caspase inhibitor DEVD. We conclude that osteocytes, the most abundant cells in bone, may be principal target cells for unique actions of intact PTH(1–84) and circulating PTH C-fragments that are mediated by CPTHRs.

This article has been cited by other articles:

				K. Horsch, H. de Wet, M. M. Schuurmans, F. Allie-Reid, A. C. B. Cato, J. Cunningham, J. M. Burrin, F. S. Hough, and P. A. Hulley Mitogen-Activated Protein Kinase Phosphatase 1/Dual Specificity Phosphatase 1 Mediates Glucocorticoid Inhibition of Osteoblast Proliferation Mol. Endocrinol., December 1, 2007; 21(12): 2929 - 2940. [Abstract] [Full Text] [PDF]

				S. Reppe, L. Stilgren, B. Abrahamsen, O. K. Olstad, F. Cero, K. Brixen, L. S. Nissen-Meyer, and K. M. Gautvik Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1465 - E1473. [Abstract] [Full Text] [PDF]

				J. Jolette, C. E. Wilker, S. Y. Smith, N. Doyle, J. F. Hardisty, A. J. Metcalfe, T. B. Marriott, J. Fox, and D. S. Wells Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1-84 in a 2-Year Study in Fischer 344 Rats Toxicol Pathol, December 1, 2006; 34(7): 929 - 940. [Abstract] [Full Text] [PDF]

				A. A. Selim, M. Mahon, H. Juppner, F. R. Bringhurst, and P. Divieti Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling Am J Physiol Cell Physiol, July 1, 2006; 291(1): C114 - C121. [Abstract] [Full Text] [PDF]

				J. Huan, K. Olgaard, L. B. Nielsen, and E. Lewin Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1923 - 1930. [Abstract] [Full Text] [PDF]

				P. A. Friedman and W. G. Goodman PTH(1-84)/PTH(7-84): a balance of power Am J Physiol Renal Physiol, May 1, 2006; 290(5): F975 - F984. [Abstract] [Full Text] [PDF]

				S. P Shrader and K. R Ragucci Parathyroid Hormone (1-84) and Treatment of Osteoporosis Ann. Pharmacother., September 1, 2005; 39(9): 1511 - 1516. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, D. C. Bauer, D. W. Dempster, L. Dian, D. A. Hanley, S. T. Harris, D. L. Kendler, M. R. McClung, P. D. Miller, W. P. Olszynski, et al. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use Endocr. Rev., August 1, 2005; 26(5): 688 - 703. [Abstract] [Full Text] [PDF]

				P. Divieti, A. I. Geller, G. Suliman, H. Juppner, and F. R. Bringhurst Receptors Specific for the Carboxyl-Terminal Region of Parathyroid Hormone on Bone-Derived Cells: Determinants of Ligand Binding and Bioactivity Endocrinology, April 1, 2005; 146(4): 1863 - 1870. [Abstract] [Full Text] [PDF]

				T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands Endocr. Rev., February 1, 2005; 26(1): 78 - 113. [Abstract] [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, A. Rakel, L. Rousseau, C. Albert, and T. Cantor Evidence That the Amino-Terminal Composition of Non-(1-84) Parathyroid Hormone Fragments Starts before Position 19 Clin. Chem., January 1, 2005; 51(1): 169 - 176. [Abstract] [Full Text] [PDF]

				D. Miao, B. He, B. Lanske, X.-Y. Bai, X.-K. Tong, G. N. Hendy, D. Goltzman, and A. C. Karaplis Skeletal Abnormalities in Pth-Null Mice Are Influenced by Dietary Calcium Endocrinology, April 1, 2004; 145(4): 2046 - 2053. [Abstract] [Full Text] [PDF]

				R. J. Midura, X. Su, J. A. Morcuende, M. Tammi, and R. Tammi Parathyroid Hormone Rapidly Stimulates Hyaluronan Synthesis by Periosteal Osteoblasts in the Tibial Diaphysis of the Growing Rat J. Biol. Chem., December 19, 2003; 278(51): 51462 - 51468. [Abstract] [Full Text] [PDF]

				F. R. Bringhurst Circulating Forms of Parathyroid Hormone: Peeling Back the Onion Clin. Chem., December 1, 2003; 49(12): 1973 - 1975. [Full Text] [PDF]

				A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220. [Abstract] [Full Text] [PDF]

				S. J. Silverberg, P. Gao, I. Brown, P. LoGerfo, T. L. Cantor, and J. P. Bilezikian Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1-84) in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4725 - 4730. [Abstract] [Full Text] [PDF]

				H. Reichel, A. Esser, H.-J. Roth, and H. Schmidt-Gayk Influence of PTH assay methodology on differential diagnosis of renal bone disease Nephrol. Dial. Transplant., April 1, 2003; 18(4): 759 - 768. [Abstract] [Full Text] [PDF]

				W. G. Goodman, I. B. Salusky, and H. Juppner New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1731 - 1736. [Full Text] [PDF]

				P. Divieti, M. R. John, H. Juppner, and F. R. Bringhurst Human PTH-(7-84) Inhibits Bone Resorption in Vitro Via Actions Independent of the Type 1 PTH/PTHrP Receptor Endocrinology, January 1, 2002; 143(1): 171 - 176. [Abstract] [Full Text] [PDF]